An interventional study of No Intervention in Pompe Disease (Late-onset), sponsored by Astellas Gene Therapies. Active, not recruiting at 53 sites in 11 countries. Open to participants aged 16 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Astellas Gene Therapies (part of Astellas Pharma Inc) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Glycogen Storage Disease Type II with a site in United States — 11 open to participants now, 20 under way, 3 of them phase 3. Glycogen Storage Disease Type II · United States.
Among the 93 studies in Glycogen Storage Disease Type II with a site in United States, this one is the 2nd largest by enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 with no phase, reaches primary completion later than 5 of the 19 other live ones, and was the 88th registered.
162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.
Browse Glycogen Storage Disease Type II studies →11 of the 93 studies in Glycogen Storage Disease Type II with a site in United States are open now. Recruiting first, the newest first:
Denali Therapeutics Inc. · Sites in United States, Germany, Netherlands and 1 more country
Ages 18–75
AskBio Inc · Sites in United States
Ages 18–65
Shionogi · Sites in United States, Belgium, Denmark and 6 more countries
Ages 18+
xCures · Sites in United States
Amicus Therapeutics · Sites in United States, Austria, Belgium and 9 more countries
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.
This study: 16 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 27 · Phase 3 10 · Phase 4 9
First in 1993; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 20 across 89 interventional studies indexed under Glycogen Storage Disease Type II.
Median enrollment 18 across the 60 interventional studies, 38 across the 30 observational. Of the 65 that completed or were terminated, 27 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 93 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Gene Therapies, one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Gene Therapies is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Astellas Pharma Inc has 2 studies filed under Glycogen Storage Disease Type II — fewer than ten, so there is no comparison to draw.
6 of the studies in Glycogen Storage Disease Type II with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03911505Phase 3Amicus TherapeuticsZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD | 2027-03 |
| NCT04808505Phase 3Amicus TherapeuticsA Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 | 2027-07 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06150820Astellas Gene TherapiesA Study About Antibody Levels and Biomarkers in the Blood in People With Late-onset Pompe Disease | 2027-06-30 |
| NCT07123155ShionogiStudy of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | 2027-08-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 93 studies in Glycogen Storage Disease Type II with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pompe disease is a genetic condition which causes muscle weakness over time. People with Pompe disease have a faulty gene that makes an enzyme called acid alpha-glucosidase (or GAA). This enzyme breaks down a type of sugar called glycogen. Without this enzyme, there is a build-up of glycogen in the cells of the body. This causes muscle weakness and other symptoms. Pompe disease can happen at any age, but in late-onset Pompe disease, symptoms generally start from 12 months old onwards.
The standard treatment for people with Pompe disease is to receive regular infusions of the GAA enzyme. This is known as enzyme replacement therapy. However, people can build up antibodies against the GAA enzyme over time.
Gene therapy is used to treat conditions caused by a faulty gene. It works by replacing the faulty gene with a working gene inside the cells of the body. The working gene is delivered into the cells using certain viruses as carriers (vectors). Viruses are often used as carriers as they can easily get inside cells. The genetic material of the original virus is replaced with the working gene, so only the working gene gets inside the cells. A common virus used as a carrier in gene therapy is the adeno-associated virus (or AAV). This is like an adenovirus, which causes the common cold.
The original type of AAV does not cause any harm to humans. However, people that have previously been infected with the original type of AAV may have built up antibodies against AAV. These antibodies may stop the AAV carrier with the working gene getting inside the cells.
Researchers want to learn more about antibody levels against AAV and the GAA enzyme in people with late-onset Pompe disease. They also want to learn about other substances in the blood that provide more information about late-onset Pompe disease. These are known as biomarkers.
In this study, older teenagers and adults with late-onset Pompe disease will take part. They will not have had gene therapy using AAV. There will be 2 groups - those who have never had enzyme replacement therapy, and those who have had enzyme replacement therapy for 6 months or more. No study treatment will be given during the study, but blood and urine samples will be taken for testing.
The main aims of the study are to check antibody levels against AAV8 (a type of AAV) in people with late-onset Pompe disease who had not received any treatment using AAV, to check antibody levels against the GAA enzyme in people previously treated with GAA as part of enzyme replacement therapy, to check levels of biomarkers for Pompe disease, and to check for medical problems.
In the study, people will visit the study clinic several times. Some visits may be in the person's home. The first visit is to check if they can take part. Those who can take part will have a medical examination, and have their vital signs checked. Vital signs include blood pressure, heart rate, breathing rate and temperature. Blood samples will be taken to check antibody levels against the GAA enzyme and against AAV8. Blood and urine samples will also be taken to check for biomarkers for Pompe disease. Blood and urine samples will be taken about every 4 months for up to 2 years.
No investigational drug will be administered to participants in this study. Blood and urine will be collected as part of the study. The duration of the study is approximately 2 years, participants may withdraw at any time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adolescent or adult participants with LOPD.
Other: No Intervention
No investigational drug will be administered to participants in this study.
Occurrence of total antibodies to AAV8
Antibodies to AAV8 will be recorded from serum blood samples collected.
Time frame: Up to 2 years
Occurrence of neutralizing antibodies to AAV8
Antibodies to AAV8 will be recorded from serum blood samples collected.
Time frame: Up to 2 years
Seroconversion of antibodies to AAV8 over time
Seroconversion of antibodies to AAV8 will be recorded from serum blood samples collected.
Time frame: Up to 2 years
Creatine kinase [CK] levels
CK levels will be recorded from blood plasma samples collected.
Time frame: Up to 2 years
Urine glucose tetrasaccharide [Glc4]/hexose tetrasaccharide [Hex4] over time
Glc4/Hex4 will be recorded from urine samples collected.
Time frame: Up to 2 years
Occurrence of anti-GAA antibodies in participants on ERT
Anti-GAA antibodies will be recorded from serum blood samples collected.
Time frame: Up to 2 years
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Jun 2027, 40 months after the start.
Of 16 interventional studies with no phase under Glycogen Storage Disease Type II, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 40 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glycogen Storage Disease Type II →